Loading company…
ONCOBIX develops pharmaceutical products, including treatments for cancer and other conditions.
Founded in 2916 and based in Gyeonggi-do, South Korea, ONCOBIX develops and manufactures drugs. Its TOFPOMICS platform is used to identify candidate compounds, and as of 2022 the company was developing a targeted fourth-generation lung cancer treatment, OBX02-011, as well as treatments for pulmonary fibrosis and pancreatic cancer. CEO Seong Kim leads the company. In September 2022, it raised KRW 4 billion in venture funding led by Korea Investment Partners and HK Inno.N Corp.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in